Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) Other Operating Expenses (2023 - 2025)

Historic Other Operating Expenses for Allogene Therapeutics (ALLO) over the last 3 years, with Q2 2025 value amounting to $2.4 million.

  • Allogene Therapeutics' Other Operating Expenses fell 5225.5% to $2.4 million in Q2 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year decrease of 9177.54%. This contributed to the annual value of $15.7 million for FY2024, which is 1866.36% up from last year.
  • According to the latest figures from Q2 2025, Allogene Therapeutics' Other Operating Expenses is $2.4 million, which was down 5225.5% from $10.7 million recorded in Q3 2024.
  • In the past 5 years, Allogene Therapeutics' Other Operating Expenses ranged from a high of $13.2 million in Q4 2023 and a low of $2.4 million during Q2 2025
  • Its 3-year average for Other Operating Expenses is $7.8 million, with a median of $7.9 million in 2024.
  • Data for Allogene Therapeutics' Other Operating Expenses shows a peak YoY increase of 5225.5% (in 2025) and a maximum YoY decrease of 5225.5% (in 2025) over the last 5 years.
  • Over the past 3 years, Allogene Therapeutics' Other Operating Expenses (Quarter) stood at $13.2 million in 2023, then decreased by 19.0% to $10.7 million in 2024, then tumbled by 77.8% to $2.4 million in 2025.
  • Its Other Operating Expenses was $2.4 million in Q2 2025, compared to $10.7 million in Q3 2024 and $5.0 million in Q2 2024.